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3Abstract:
Background: Anti-PD1/PD-L1 directed immune-checkpoint-inhibitors (ICI) are widely 
used to treat patients with advanced non-small cell lung cancer (NSCLC). The activity 
of ICI across NSCLC harboring oncogenic alterations is poorly characterized. The aim 
of our study was to address the efficacy of ICI in the context of oncogenic addiction.
Patients and methods: We conducted a retrospective study for patients receiving ICI 
monotherapy for advanced NSCLC with at least one oncogenic driver alteration. 
Anonymized data were evaluated for clinicopathologic characteristics and outcomes 
for ICI therapy: best response (RECIST 1.1), progression-free survival (PFS) and 
overall survival (OS) from ICI initiation. The primary endpoint was PFS under ICI. 
Secondary endpoints were best response (RECIST 1.1) and overall survival (OS) 
from ICI initiation.
Results: We studied 551 patients treated in 24 centers from 10 countries. The 
molecular alterations involved KRAS (n=271), EGFR (n=125), BRAF (n=43), MET 
(n=36), HER2 (n=29), ALK (n=23), RET (n=16), ROS1 (n=7), and multiple drivers 
(n=1). Median age was 60 years, gender-ratio was 1:1, never/former/current smokers 
were 28/51/21% respectively, and the majority of tumors were adenocarcinoma. The 
objective response rate by driver alteration was: KRAS=26%, BRAF=24%, 
ROS1=17%, MET=16%, EGFR=12%, HER2=7%, RET=6%, ALK=0%. In the entire 
cohort, median PFS was 2.8 months, OS 13.3 months and the best response rate 19%. 
In a subgroup analysis, median PFS (in months) was 2.1 for EGFR, 3.2 for KRAS, 2.5 
for ALK, 3.1 for BRAF, 2.5 for HER2, 2.1 for RET, and 3.4 for MET. In certain 
subgroups, PFS was positively associated with PD-L1 expression (KRAS, EGFR) and 
with smoking status (BRAF, HER2). 
Conclusions: ICI induced regression in some tumors with actionable driver 
alterations, but clinical activity was lower compared to the KRAS group and the lack of 
response in the ALK group was notable. Patients with actionable tumor alterations 
should receive targeted therapies and chemotherapy before considering 
immunotherapy.
Key words: Immunotherapy-lung cancer-oncogenic addiction
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4Key message:
Question: Is Immunotherapy efficient in patients with lung cancer and harboring an 
oncogenic addiction?
Findings: Patients’ outcome treated with ICI monotherapy were consistent with ICI 
registration trials in the KRAS-subgroup but were inferior for patients with actionable 
driver mutations.
Meaning: ICI should thus only be considered after exhaustion of targeted and 
standard therapies.
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5Introduction
The management of patients with stage 4 non-small cell lung cancer (NSCLC) is 
currently undergoing significant transformation. Molecular testing, targeted therapies 
and immunotherapy are now part of routine clinical care [1]. Targeted therapies are 
efficient in the context of oncogenic driver mutations [2]. These treatments are 
associated with high response rate, but also with unavoidable development of 
resistance and tumor recurrence [3]. Therapeutic options are restrained in patients 
after exhaustion of targeted therapies and chemotherapy. Immune checkpoint 
inhibitors (ICI) which block the Programmed Death-1 (PD-1) /Programmed Death 
Ligand 1 (PD-L1) axis are a new standard of care [4-6]. ICI response rates in general 
are approximately 20% in unselected NSCLC, but overall survival benefit was well 
documented in registration trials [7-10].
Whether ICIs alone or even in combination with TKIs would offer comparable benefit 
in oncogene addicted subtypes of NSCLC as much as in the general unselected 
NSCLC population has been raised as a relevant question [11]. We may expect that 
immunotherapy may transform the important tumor responses achieved with targeted 
inhibitors in prolonged remissions. Nevertheless, data obtained from subgroups in 
clinical trials [9,10,12] and from investigators observations have shown rather weak 
activity of ICI in NSCLC patients harboring actionable driver mutations [13]. Therefore, 
the optimal use of ICI therapy in patients with actionable driver mutations remains an 
important field of ongoing research. 
The purpose of this study was to analyze the clinical activity of ICI therapy in the context 
of oncogenic driver alterations. We previously conducted registry studies on targeted 
therapies for NSCLC with ROS1, HER2, BRAF and RET alterations [14-18]. We used 
our established network to perform a wide international cohort of patients with 
molecularly defined NSCLC. Hereinafter, we present the results for the whole cohort, 
and for individual molecular subgroups.
Patients and methods
Study objectives. 
The primary objective of our study was to describe the progression-free survival (PFS) 
of patients treated with PD1/PD-L1 checkpoint inhibitors (ICI) in each subgroup 
carrying an oncogenic driver. The secondary objectives were both the best overall 
response (that was not confirmed by a second measurement) and the overall survival 
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6for each molecular subgroup. We also analyzed the outcome of patients according to 
smoking status, line of treatment, and PD-L1 expression. 
Patients’ selection 
A global multicenter network of thoracic oncologists accrued patients in this registry. 
Investigators were identified via an ongoing collaboration established by our prior 
registries [14-18]. Eligible patients had 1) a pathological diagnosis of lung cancer; 2) 
local testing positive (either direct sequencing or NGS on validated platforms) for at 
least one oncogenic driver mutation: EGFR (exon 18-21) activating mutation, HER2 
(exon 20) activating mutation, KRAS mutation, BRAF (exon 15) mutation, MET 
amplification or exon 14 mutation, ALK rearrangement, ROS1 rearrangement or RET 
rearrangement; 3) single agent ICI therapy with commercial anti-PD1/PD-L1-
antibodies; 4) local response assessment according to RECIST1.1 criteria; 5) follow-
up with survival status. Optionally, investigators were asked to record immunotherapy-
related adverse events (irAE), and PD-L1 expression in tumor cells. 
PD-L1 analysis
PD-L1 analysis was performed in each center according to local procedures. 
Antibodies used were E1L3N (32.8%), SP142 (31.7%), 22C3 (22.2%), SP263 (6.7%), 
28-8 (5.6%), and others (1.1%). Results were provided in percentage of staining of 
tumor cells with 3 cut-off levels: 1%, 10% and 50%.
Ethical considerations
The study was approved by the national ethics committees of France (CEPRO 2017-
043, CNIL Nh22181405I) and Switzerland (Swissethics/EKNZ ID 2017-01530). 
Participating centers were responsible for patients’ consent and institutional approval. 
All contributors were trained in Good Clinical Practice. The study was a purely 
academic collaboration granted by both Toulouse and Lucerne Hospitals and was not 
funded by industry. 
Data collection and response assessment
Anonymized clinical data were recorded by local investigators using electronic case 
report forms (eCRF) in a password-protected secure online portal from the University 
of Toulouse [https://ec.claudiusregaud.fr/CSOnline/]. Data were centrally collected at 
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7the University of Toulouse (France). The registry was open for enrolment from May 
2017 until April 2018. Best response to systemic therapies, defined as a complete or 
partial response achieved at least once during the course of therapy, was assessed 
locally using RECIST v1.1 criteria. Patients treated in clinical trials were not included 
in our study.
 
Statistical methods
All statistical evaluations were performed according to the predefined plan as stated in 
the protocol. Data were summarized according to frequency and percentage for 
qualitative variables, and by median and range for quantitative variables. The 95% 
confidence interval for response rate was calculated using the exact binomial 
distribution. PFS was measured as the time from the first administration of ICI therapy 
to progression defined by RECIST1.1, or death due to any cause. Patients alive without 
progression at the time of analysis were censored at the initiation of a new therapy or 
last follow-up. Overall survival was measured as the time from the first administration 
of ICI therapy to death due to any cause. Patients alive at the time of analysis were 
censored at the last follow-up. Survival data were estimated using the Kaplan–Meier 
method and compared using the log-rank test in overall cohort and oncogenic driver 
subgroups. Statistical analyses were carried out using STATA 13.1 software 
(StataCorp, TX, USA).
Results
Patients’ characteristics
During an enrolment phase of almost one year, the registry included 551 patients from 
24 centers in 10 countries. The molecular alterations involved KRAS (n=271), EGFR 
(n=125), BRAF (n= 43, V600E n=17, other n=18), MET (n=36, MET amplification n=13, 
exon 14 skipping mutation n=23), HER2 (n=29), ALK (n=23), RET (n=16), ROS1 (n=7). 
34 patients with more than one driver were allocated to the dominant oncogenic driver. 
Details are provided in the supplementary data (S1 and S2). Median age was 60 years 
(range: 29-83). Gender-ratio was 1:1. Smoking status was 28% never-smokers, 51% 
former smokers, and 21% current smokers. The majority (96%) of tumors were 
adenocarcinoma. At the time of immunotherapy initiation, most patients had ECOG 
Performance Status (PS) of 1 (64%), while fewer patients were PS0 (21%), PS2 (11%), 
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8and PS3/4 (4%). All patients presented an advanced tumor stage at the beginning of 
immunotherapy. The clinical characteristics of each subgroup are reported in Table 1.
Treatment characteristics and safety
Most (94%) patients received anti-PD1-antibodies (nivolumab n = 466, pembrolizumab 
n = 48, other n = 6), fewer patients (6%) had anti-PD-L1-antibodies (atezolizumab n = 
19, durvalumab n = 11, other n = 1). ICIs were given in the first (5%), second (41%), 
third (26%), fourth line (13%) or in later lines (14%) of treatment (supplementary S3). 
The recording of significant (grade 3-4) immunotherapy-related adverse events (irAE) 
was optional. From 462 patients with available data, 50 (10.8%) had grade 3-5 irAEs, 
including 36 (7.8%) of grade 3, 13 (2.8%) of grade 4 and 1 of grade 5 (0.2%, endocrine 
disorder). The pneumonitis rate was in the expected range (13 cases, 2.8% including 
8 grade 3 and 5 grade 4). No unexpected irAEs were recorded. 
PD-L1 expression
PD-L1 status was available for 214 patients. The median number of positive cells was 
10%. Using a 1% cut-off, one third were negative (33.2%) and two-third positive 
(66.8%). Using a 10% cut-off, half of the tumors was negative (49.7%) and half positive 
(50.3%). Using a 50% cut-off, one-third of the tumors was positive (33.9%). Looking 
into each subgroup, we found that median percentage of cells expressing PD-L1 was 
0 in HER2 (n= 13), 3.5 in EGFR (n=38), 7.5 in ALK (n=10), 12.5 in KRAS (n=80), 26 in 
RET (n=6), 30 in MET (n=15), 50 in BRAF (n=9) and 90 in ROS1 (n=5) subgroups 
(supplementary S4 and S5).
Clinical outcomes
Response rate
The rate of any partial or complete response was 19% [95%CI: 16-23%], ranging from 
0% in ALK patients to 26% in KRAS mutated patients. If we consider the KRAS patients 
as a control group and exclude them from the analysis, the best response rate for 
patients harboring all other molecular alterations was 12.7%. We then classified the 
subgroups according to the rate of progressive disease. Progressive disease (PD) was 
observed in 46% for BRAF, 50% for MET, 51% for KRAS, 67% for HER2, 67% for 
EGFR, 68% for ALK, 75% for RET and 83% for ROS1. Fig. 1, supplementary S6. 
Details according to mutation subtype are in supplementary table S7.
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9Overall survival
In the entire cohort, median follow-up was 16.1 months, and median OS from start of 
ICI therapy was 13.3 months [10.0-14.9] (Fig. 2). Median OS (in months) for individual 
molecular subgroups was 10.0 [6.7;14.2] for EGFR mutated patients, 13.5 [9.4;15.6] 
for KRAS, 17.0 [3.6;NR] for ALK, 13.6 [7.4;22.5] for BRAF, 20.3 [7.8;NR] for HER2, 
21.3 [3.8;28.0] for RET and 18.4 [7.0;NR] for METS7. In the univariate analysis, OS 
did not correlate with gender, age, smoking, number of prior therapies, or PD-L1 
expression (supplementary S8).
Progression-free survival
In the entire cohort, median PFS was 2.8 months [95%IC 2.5-3.1]. Median PFS (in 
months) for individual molecular subgroups was 2.1 [1.8;2.7] for EGFR, 3.2 [2.7;4.5] 
for KRAS, 2.5 [1.5;3.7] for ALK, 3.1 [1.8;4.6] for BRAF, 2.5 [1.8;3.5] for HER2, 2.1 
[1.3;4.7] for RET and 3.4 [1.7;6.2] for MET (Fig. 2). Long-term responders were more 
frequent in KRAS (12-months PFS: 25.6 %), MET (23.4%) and BRAF (18.0%) 
subgroups, than in EGFR (6.4%), ALK (5.9%), HER2 (13.6%) and RET (7.0%) 
subgroups (Table 2). If we exclude KRAS patients from the analysis (n=279 patients 
with all other alterations), median PFS was 2.4 months.
In the univariate analysis, PFS significantly correlated with smoking (median PFS: 2.5, 
2.8 and 3.5 months for never smokers, former smokers and current smokers, 
respectively, p < 0.0001), and with PD-L1 expression (3.0 vs 4.2 months for negative 
and positive expression of PD-L1, p = 0.02). However, PFS did not correlate with 
gender (p = 0.5), age (p = 0.3) or number of previous lines of treatment (p = 0.08). 
(supplementary S9 and S10). Interestingly, a higher rate of rapid progression (within 2 
months) was observed for EGFR (44.8%), ALK (45.5%), ROS1 (42.9%) and RET 
(43.8%) patients than for KRAS (36%) (supplementary S11) respectively. 
Molecular subgroup analyses
KRAS mutations were identified in 271 patients. PFS was not significantly different 
regarding KRAS mutation subtype if we compare G12C (n = 100) to other mutations 
(n = 143, p = 0.47) or G12D (n = 39) vs other KRAS mutations (n = 204, p = 0.40). PFS 
did also not correlate with smoking (p = 0.98), or with the number of previous lines of 
treatment. In patients with available PD-L1 expression data (n = 95), PD-L1 positive 
expression was significantly (p = 0.01) correlated with a longer PFS (median PFS: 7.2 
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vs 3.9 months) (Fig 3). We also separate patients harbouring KRAS transition (G12D, 
G13D, G12S) from KRAS transversion (G12C, G12A, G12V, G13C). PFS was not 
impacted by the nature of KRAS alteration (2.9 months for transition, 4.0 for 
transversion, p = 0.27, (supplementary S12).
PFS was significantly different across EGFR molecular subgroups ranging from 1.4 
month in T790M and complex mutations subgroup to 1.8 for exon 19, 2.5 for exon 21 
and 2.8 for other mutations (p < 0.001). PFS correlated neither with smoking (p = 0.06), 
nor with the number of previous lines of treatment. PD-L1 positivity was significantly 
correlated with a longer PFS (2.8 months vs. 1.7, p=0.01) (Fig 3).
For BRAF patients, PFS was significantly higher in smokers vs. never smokers (4.1 vs. 
1.9 months, p = 0.03). Median PFS was numerically shorter in the V600E subgroup 
(1.8 months) compared to other BRAF mutations (4.1 months, p = 0.20). 
MET molecular alterations were found in 36 patients. Median PFS correlated neither 
with alteration subtype (exon 14 skipping mutation vs other MET alterations, p = 0.09), 
nor with smoking.
HER2 mutations were identified in 29 patients. PFS correlated with smoking (3.4 
months for smokers vs 2.0 months for never smokers, p = 0.04).
Due to a low number of patients, ALK, ROS1 and RET were analyzed together in a 
subgroup termed “rearrangements”. Median PFS was only slightly higher in never-
smokers (2.6 months) than in smokers (1.8 months, p = 0.03). PD-L1 was not available 
in enough patients but no tumor response was reported in patients from this group in 
the context of PD-L1 positivity. (supplementary S13, S5). Main results for all cohorts 
are presented in supplementary S14.
Discussion
The standard of care for patients with actionable driver alterations is a targeted therapy. 
After exhaustion of targeted agents and chemotherapy, immunotherapy may be 
considered as a salvage treatment. Nevertheless, evidence to support the role of ICI 
in this setting is controversial, as EGFR and ALK alterations have been associated with 
low ICI efficacy in prior studies [19]. To address this issue, we conducted a global "real 
world" study. Our study was retrospective and had other limitations, including reporting 
bias, lack of central molecular and radiologic assessment, and variable scanning 
intervals. Nevertheless, we obtained new findings of clinical relevance. 
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In the overall cohort, the best response with ICI therapy by RECIST was 19%, and 
median PFS was 2.8 months. This result was mainly driven by the large KRAS 
subgroup, and it is in concordance with registration trials testing immunotherapy in 
pretreated patients, regardless EGFR or ALK status [9][10]. Regarding molecular 
subgroups, we confirmed that patients with KRAS-mutant NSCLC derived a greater 
benefit from ICI than EGFR-mutant NSCLC, as previsously reported [9]. It has been 
reported that KRAS-mutant NSCLC are more likely to express PD-1 and PD-L1 [20]. 
In our study, we have not been able to detect a significant correlation between KRAS 
mutation subtypes and PFS, but we confirmed that PD-L1 expression is associated 
with a better outcome. The limited number of patients with available PDL1 status and 
the heterogeneity of the tests did not allow us to draw a definitive conclusion on its 
potential interest. Recently, STK11/LKB1 co-mutation in KRAS-mutant NSCLC was 
reported as a new predictive marker for tumor resistance to ICI therapy [21]. STK11 
was not part of routine testing and our study did not include tissue collection, therefore, 
future studies will have to validate this interesting finding in a larger cohort. ICI are thus 
an adequate treatment for KRAS mutated patients. 
Concerning patients with EGFR mutation, the role of ICI therapy is still controversial. 
Recent studies showed an inverse relationship between PD-L1 expression and EGFR 
mutations. Moreover, an uninflamed tumor microenvironment is often reported in the 
context of oncogenic addiction [22,23]. Gainor et al. also suggested that a dearth of 
tumor-infiltrating CD8+ lymphocytes, may explain the low response rate to PD-1 axis 
inhibitors observed amongst EGFR- and ALK-driven NSCLC [24]. A recent meta-
analysis including 3 randomized trials of immunotherapy in TKI-pretreated patients 
reported that ICI do not improve OS compared to docetaxel in patients with EGFR-
mutant NSCLC [25]. In addition, a recent phase II trial of pembrolizumab in TKI-naive 
patients with PD-L1 positive EGFR-mutant NSCLC showed no RECIST responses in 
the first 11 patients [26]. In the phase II trial ATLANTIC of durvalumab in EGFR/ALK 
mutant NSCLC, response rate was 3.6% for PD-L1 < 25%, and 12.2% for PD-L1 > 
25%. Median PFS was 1.9 month [19]. Benefit has, however, been reported in patients 
with EGFR mutations with the combination of carboplatin, paclitaxel, bevacizumab and 
atezolizumab in the IMpower150 trial [5]. 
BRAF mutations were associated with slightly better outcomes compared to EGFR 
mutations (RR 24% and PFS 3.1 months). The potential efficacy of immunotherapy in 
BRAF mutant melanoma has already been suggested [27]. Recently, Dudnik et al. 
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reported frequent expression of PDL1 and comparable PFS (3.7 months) in BRAF 
V600E mutated patients [28]. In our study, PFS in patients with BRAF-mutant NSCLC 
was positively associated with smoking status. It thus appears that immunotherapy 
may be considered in BRAF positive patients after targeted therapy and one line of 
chemotherapy. 
ALK, ROS1 and RET translocation represent a small subgroup of NSCLC. In our study, 
PD-L1 expression was relatively high in those cases. However, most tumors were 
refractory to ICI therapy. These observations were consistent with other studies, 
namely with ATLANTIC for ALK, and with a cohort study from MSKCC for RET [29]. 
Although these data are preliminary, we do not recommend ICI as single agents in 
patients with ALK/ROS1/RET rearranged NSCLC.  
In conclusion, patients’ outcome treated with ICI monotherapy overall were consistent 
with ICI registration trials, based on the large KRAS-subgroup in our study. However, 
outcomes for patients with actionable driver mutations (EGFR, ALK, ROS1) were 
inferior and ICI should only be considered after exhaustion of targeted therapies and 
in some cases, potentially in all other therapies including standard and salvage 
chemotherapies. We think that there are two ways to optimize the use of 
immunotherapy in the context of oncogenic addiction. The first one is to combine 
immunotherapy with other drugs such as chemotherapy and anti-angiogenic agents. 
The second one is to identify new relevant biomarkers besides PD-L1 expression and 
TMB considering the complex molecular biology of NSCLC.
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NOTE
Preliminary results were presented at the ASCO-SITC meeting (2018 January 26th, 
San Francisco, abstract #172) and at the ASCO Annual Meeting, (2018 June 1st, 
abstract #9010, oral communication in Clinical Science Symposium).
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Table 1: Clinical and biological description according to mutation type
EGFR
N=125
KRAS
N=271
ALK
N=23
BRAF
N=43
ROS1
N=7
HER2
N=29
RET
N=16
MET
N=36
Gender (n=551)
Male
Female
48
77
38.4%
61.6%
141
130
52%
48%
12
11
52.2%
47.8%
24
19
55.8%
44.2%
5
2
71.4%
28.6%
15
14
51.7%
48.3%
7
9
43.8%
56.3%
21
15
58.3%
41.7%
Smoking (n=551)
Never Smoker
Former Smoker
Current Smoker
missing
78
38
7
2
63.4%
30.9%
5.7%
12
168
80
11
4.6%
64.6%
30.8%
10
8
3
2
47.6%
38.1%
14.3%
11
22
9
1
26.2%
52.4%
21.4%
5
2
0
71.4%
28.6%
0%
14
12
1
2
51.9%
44.4%
3.7%
10
4
1
1
66.7%
26.7%
6.7%
8
15
11
2
23.5%
44.1%
32.4%
Histological Type (n=551)
Adenocarcinoma
Squamous
Sarcomatoid
Large cell carcinoma
Not specified/other/missing
121
1
0
0
3
96.8%
0.8%
0%
0%
2.4%
262
0
1
6
2
96.7%
0%
0.4%
2.2%
0.7%
21
0
0
1
1
91.3%
0%
0%
4.3%
4.3%
40
1
0
1
1
93%
2.3%
0%
2.3%
2.3%
6
0
0
0
1
85.7%
0%
0%
0%
14.3%
28
0
0
1
0
96.6%
0%
0%
3.4%
0%
14
0
0
1
1
87.5%
0%
0%
6.3%
6.3%
34
0
1
0
1
94.4%
0%
2.8%
0%
2.8%
Age at Diagnosis (n=551)
Median (year) 
Range (year)
60
33-80
59
30-83
55
30-73
61
42-75
45
42-67
62
31-77
54.5
29-73
63
40:82
D
ow
nloaded from
 https://academ
ic.oup.com
/annonc/advance-article-abstract/doi/10.1093/annonc/m
dz167/5498206 by U
niversity of Torino user on 04 June 2019
Table 2: PFS according to primary oncogenic driver from initiation of ICI
EVT/N Median PFS [95%CI] 
(months)
6-months PFS [95%CI] 12-months PFS 
[95%CI]
KRAS 208/271 3.2 [2.7; 4.5] 37.9 [32.1; 49.8] 25.6 [20.2; 31.3]
EGFR 117/125 2.1 [1.8; 2.7] 18.4 [12.1; 25.6]   6.4 [2.7; 12.1]
BRAF 34/43 3.1 [1.8; 4.6] 32.1 [18.3; 46.6] 18.0 [7.2; 32.7]
HER2 23/29 2.5 [1.8;3.5] 22.7 [8.9; 40.2] 13.6 [3.6; 30.1]
MET 26/36 3.4 [1.7; 6.2] 36.5 [20.7; 52.4] 23.4 [10.6; 39.0]
ALK 21/23 2.5 [1.5; 3.7] 11.8 [2.2; 30.2]   5.9 [ 0.4; 23.0]
ROS1 - - - -
RET 15/16 2.1 [1.3; 4.7] 14.1 [2.3; 35.9]   7.0 [0.4; 27.1]
EVT Event; N Number
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 Figure 1: Best response to ICI according to RECIST criteria (PD Progressive disease, SD Stable disease, PR 
Partial response, CR Complete Response). 
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 Figure 2: Overall survival (on the left) and progression-free survival (on the right) in the whole cohort 
(upper figures) and in each subgroup (lower figures). 
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 Figure 3: PFS according to oncogenic drivers’ variants and PDL1 expression. 
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S3: 
N %
Anti PD1 n=520
Nivolumab
Pembrolizumab
Other
466
48
6
89.6
9.2
1.2
Anti PDL1 n=31
Atezolizumab
Durvalumab
Other
19
11
1
59.4
34.4
3.1
Line Immunotherapy n=551
1st line
2nd line
3rd line
4th line
>4th Line
30
227
144
73
77
5.4
41.2
26.1
13.2
14
Duration of the line (months) 
n=485
Median
Range
missing
2.1
0.03-27.4
66
Number of injections n=470
Median
Range
Missing
5
1-68
81
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S4:
EGFR
N=125
KRAS
N=271
ALK
N=23
BRAF
N=43
ROS1
N=7
HER2
N=29
RET
N=16
MET
N=36
PDL1 Status available N = 49 N = 95 N = 11 N = 10 N = 5 N = 15 N = 8 N = 20
PDL1 Status 
Negative 
Positive (>1%)
18
31
36.7%
63.3%
32
63
33.7%
66.3%
4
7
36.4%
63.6%
3
7
30%
70%
0
5
0%
100%
7
8
46.7%
53.3%
2
6
25%
75%
5
15
25%
75%
% of tumor cells 
PDL1 staining <10%
≥10%
missing
21
17
11
55.3%
44.7%
39
41
15
48.8%
51.3%
5
5
1
50%
50%
3
6
1
33.3%
66.7%
0
5
0
0%
100%
11
2
2
84.6%
15.4%
3
3
2
50%
50%
6
9
5
40%
60%
% of tumor cells 
PDL1 staining <50%
≥50%
missing
27
11
11
71.1%
28.9%
54
26
15
67.5%
32.5%
6
4
1
60%
40%
4
5
1
44.4%
55.6%
2
3
0
40%
60%
13
0
2
100%
0%
3
3
2
50%
50%
8
7
5
53.3%
46.7%
% of tumor cells 
PDL1  positive 
Median
Range
missing
3.5
0-90
11
12.5
0-100
15
7.5
0-90
1
50
0-90
1
90
20-100
0
0
0-25
2
26
0-80
2
30
0:100
5
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S6:
Treatment Best response
CR/PR* SD PD
N % N % N % Missing
Total 97 19.4 119 23.8 283 56.7 52
KRAS 64 26 57 23.2 125 50.8 25
EGFR 14 12.2 24 20.9 77 67 10
BRAF 9 24.3 11 29.7 17 45.9 6
HER2 2 7.4 7 25.9 18 66.7 2
MET 5 15.6 11 34.4 16 50 4
ALK 0 0 6 31.6 13 68.4 4
ROS 1 16.7 0 0 5 83.3 1
RET 1 6.3 3 18.8 12 75 0
*Complete Response CR, Partial Response PR, Stable disease (SD), Progressive Disease (SD)
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S7:
EVT/N Median OS [95%CI] (Months) p
KRAS
G12C 51/100 15.6 [11.0; 19.6] 0.69
Other 78/143 10.0 [7.5; 14.8]
EGFR
T790 single or multiple 21/30 5.6 [2.8; 15.9] 0.03
Exon19 19/23 4.9 [3.2; 10.8]
Exon21 19/28 10.9 [3.9; 15.4]
other 16/35 12.8 [8.5; NR]
BRAF
V600E 11/17 8.2 [1.1; NR] 0.28
Other 9/18 17.2 [2.7; NR]
MET
Exon14 yes 9/23 25.0 [18.4; NR] 0.00
Exon14 no 7/10 8.0 [1.0; 11.4]
EVT Event; N Number; NR Not Reached
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S8:
EVT/  N Median OS [95%CI] 
(Months)
p
Gender :
Male
Female
139 / 274
161 / 277
13.6    [  9.4; 16.4]
11.4    [  9.6; 15.4]
p = 0.92
Age at diagnosis
<= 60 years
> 60 years
157 / 284
143 / 267
11.3    [  9.4; 14.9]
13.6    [ 10.0; 17.0]
p = 0.73
Smoking :
Never smoker
Former smoker  
Current smoker
89 / 148
145 / 269
60 / 113
10.9    [  8.2; 15.0]
13.6    [ 10.0; 17.0]
11.0    [  8.0; 16.4]
p = 0.69
Stage at diagnosis
IA-IIIA    
IIIB-IV   
48 /  99
246 / 443
15.2    [ 11.1; 24.0]
13.0    [  9.4; 14.8]
p = 0.11
Line Immunotherapy
1st-3rd line
> 3rd line
206 / 401
94 / 150
13.6    [ 10.0; 16.4]
10.8    [  7.6; 14.3]
p = 0.07
* If PDL1 done,
PDL1 status :
Negative
Positive (>1%)
34 /  71
61 / 143
16.0    [ 11.3; 20.5]
15.6    [ 14.2; 26.3]
p = 0.57
% of tumor cells PDL1
<10%
>=10%        
38 /  88
31 /  89
16.4    [ 11.3; 24.0]
18.4    [ 14.3; NR]
p = 0.52
% of tumor cells PDL1
<50%
>=50%
48 / 117
21 /  60
17.1    [ 13.6; 24.0]
18.4    [ 11.4; NR]
p = 0.65
% of tumor cells PDL1
0%
1-49%
50-100%
34 /  71
14 /  46
21 /  60
16.0    [ 11.3; 20.5]
NR    [   7.4; NR]
18.4    [ 11.4; NR]
p = 0.51
EVT Event; N Number; NR Not Reached
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S10:
EVT/N Median PFS [95%CI]
(Months)
p
KRAS
G12C 72/100 5.5 [2.7; 7.9] 0.47
Other 112/143 3.1 [2.5; 4.5]
EGFR
T790 single or multiple 30/30 1.4 [1.1; 1.9] P<0.0001
Exon19 23/23 1.8 [1.4; 2.7]
Exon21 25/28 2.5 [1.5; 4.3]
other 32/35 2.8 [2.1; 5.2]
BRAF
V600E 14/17 1.8 [1.0; 4.6] p=0.20
Other 14/18 4.1 [2.0; 9.0]
MET
Exon14 yes 17/23 4.7 [1.8; 7.8] 0.09
Exon14 no 8/10 1.3 [0.6; 6.2]
EVT Event; N Number
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S9:
EVT/  N Median PFS [95%CI] 
(Months)
p
Gender 
Male
Female
217/274
232/277
2.9 [2.4; 3.4]
2.7 [2.2; 3.2]
p=0.57
Age at diagnosis
<= 60 years
> 60 years
233/284
216/267
2.5 [2.1; 2.8]
3.1[2.7; 3.5]
p=0.29
Smoking 
Never smoker
Former smoker  
Current smoker
136/148
216/269
81/113
2.5 [1.8; 2.8]
2.8 [2.3; 3.3]
3.5 [2.4; 6.2]
p<0.0001
Stage at diagnosis
IA-IIIA    
IIIB-IV   
79/99
361/443
3.3 [2.5; 4.6]
2.7 [2.3; 3.0]
p=0.31
Line Immunotherapy
1st-3rd line
> 3rd line
318/401
131/150
2.9 [2.5; 3.4]
2.5 [1.9; 2.7]
p=0.08
* If PDL1 done,
PDL1 status :
Negative 
Positive (>1%)
60/71
100/143
3.0 [2.1; 3.9]
4.2 [2.8; 5.8]
p=0.02
% of tumor cells PDL1
<10%
>=10%        
73/88
56/89
2.9 [2.3; 3.9] 
4.7 [2.6; 7.0]
p=0.02
% of tumor cells PDL1
<50%
>=50%
91/117
38/60
3.1 [2.3; 4.1]
4.7 [2.5; 7.2]
p=0.15
% of tumor cells PDL1
0%
1-49%
50-100%
60/71
31/46
38/60
3.0 [2.1; 3.9]
4.0 [2.0; 8.0]
4.7 [2.5; 7.2]
p=0.08
EVT Event; N Number
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S11: Rate of hyperprogression 
N=540
100%
Progression within 2 months
N=212
39.2%
No Progression at 2months
N=328
60.8%
Type of primary 
mutation
EGFR 125 56 (44.8%) 69 ( 55.2%)
KRAS 267 96 ( 36.0%) 171 ( 64.0%)
ALK 22 10 ( 45.5%) 12 ( 54.5%)
ROS1 7 3 ( 42.9%) 4 ( 57.1%)
BRAF 42 17 ( 40.5%) 25 ( 59.5%)
HER2 28 11 ( 39.3%) 17 ( 60.7%)
RET 16 7 ( 43.8%) 9 ( 56.3%)
MET 33 12 ( 36.4%) 21 ( 63.6%)
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S12: Overall survival and Progression free survival according to KRas type of mutation: Transition vs Transversion 
KRas mutation type N (Total=271) %
Transition 53 22
Transversion 188 78
Missing 30
EVT / N Median OS or PFS months 
[95%CI]
p
OS
Transition 32 / 53 7.4 [5.8; 14.3] 0.3043
Transversion 96 / 188 14.3 [9.8; 17.8]
PFS
Transition 44 / 53 2.9 [2.1; 4.5] 0.2688
Transversion 138 / 188 4.0 [2.8; 5.9]
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S13: 
PDL1
Neg
Median PFS 
[95%CI]
>1%
Median PFS 
[95%CI]
 
p
Smoking
Never
Median PFS 
[95%CI]
Current 
or former
Median PFS 
[95%CI]
 
p
ICI line
1st-3rd
Median PFS 
[95%CI]
>3rd
Median PFS 
[95%CI]
p
Variant Median PFS 
[95%CI] p
KRAS 3.9[1.7; 6.8] 7.2[4; 14.4] 0.01 4.6[1.6; 8.4] 3.1[2.7; 4.0] 0.98 3.2[2.7; 4.5] 3.1[1.9; 7.1] 0.66 G12C 
G12A
G12D
G12V
G12S
Other
5.5[2.7; 7.9]
4.4[2.1; 10]
3.2[2.4. 5.3]
1.9[1.6. 5.1]
2.1[1.1. NR]
2.8[2.0; 10.7]
0.90
EGFR 1.7[1.2; 2.7] 2.8[1.9; 7.2] 0.01 2.1[1.7; 2.7] 2.4[1.9; 3.7] 0.06 2.5[2; 3.5] 1.9[1.6; 2.6] 0.19
BRAF -* -* na 1.9[0.7; 4.1] 4.1[1.8; 7.8] 0.03 3.1[1.5; 4.8] 2.7[1.6, NR] 0.58
HER2 -* -* na 2.0[1.5; 2.9] 3.4[1.6; NR] 0.04 2.9[1.8; 5.4] 2.0[1.2; .] 0.30 -* -*
MET -* -* na 5.8[1.3; NR] 3.4[1.7; 6.9] 0.92 -* -* na
ALK/ROS/RET -* -* na 2.6[1.7; 4.7] 1.8[1.4; 2.2] 0.03 1.8[1.3; 3.8] 2.6[1.8; 3.7] 0.46
-*: not enough events to perform the univariate analysis
NR Not Reached
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